Compelling case that $1.50 CTIX is greatly un

Compelling case that $1.50 CTIX is greatly undervalued!

Article excerpt below:

Cellceutix isn't even fairly valued based solely on conducting a clinical trial at Harvard's Dana-Farber Cancer Center and partner Beth Israel Deaconess Medical Center. Take a look at this table:

A simple look shows that Cellceutix is only at about half of the market cap of any other of even the smallest of companies at the time that they began clinical trials at Dana-Farber. A closer look reveals that Cellceutix has actually appreciated to these current levels and was even more undervalued compared to peers, but is making-up ground as trials progress.

A more discerning examination shows that Kevetrin being tested against multi-drug resistant solid tumors is a far, far larger market than any of the indications that were tested by other companies. To me, Cellceutix should be valued at a minimum of $2 based on the Dana-Farber/Kevetrin connection, giving it an immediate 33% upside.

Further, none of those companies had a drug remotely as exciting or as much of a breakthrough as Cellceutix, so it should already have an even greater value, perhaps $2.50 or so. I suspect as clinical data starts being collected in 2013, Cellceutix's valuation will climb to the top of those valuations and probably much higher.

h/t: The Progressive